Cited 0 times in Scipus Cited Count

Efficacy and drug retention of tofacitinib in rheumatoid arthritis: from the nationwide Korean College of Rheumatology Biologics registry

DC Field Value Language
dc.contributor.authorJung, JY-
dc.contributor.authorLee, E-
dc.contributor.authorKim, JW-
dc.contributor.authorSuh, CH-
dc.contributor.authorKim, HA-
dc.date.accessioned2023-06-14T02:52:27Z-
dc.date.available2023-06-14T02:52:27Z-
dc.date.issued2023-
dc.identifier.issn0392-856X-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/25931-
dc.description.abstractOBJECTIVES: Janus kinase inhibitors are expected to change the management patterns and prognosis of chronic rheumatic diseases. This study aimed to evaluate the efficacy, drug retention, and adverse events of tofacitinib, a Janus kinase inhibitor, for rheumatoid arthritis (RA) using a Korean nationwide database. METHODS: Data of patients with RA receiving tofacitinib were extracted from the Korean College of Rheumatology Biologics and Targeted Therapy registry, including clinical characteristics and disease activity markers for RA. Outcomes of clinical efficacy, drug survival rate, and safety profiles were compared between biologic disease-modifying anti-rheumatic drug (bDMARD)-naive and -failure patients. Mann-Whitney U-test, logistic regression analysis, Kaplan-Meier analysis, and log-rank test were used in data analysis. RESULTS: Three hundred patients with RA received tofacitinib therapy (16.3% male; mean age 55.4±11.9 years); 91 patients were bDMARD-naive. Baseline disease activity markers and proportions of patients who were taking conventional synthetic DMARDs were not different between bDMARD-naive and bDMARD-failure patients. American College of Rheumatology responses and disease activity score-28 did not differ between bDMARD-failure and -naive patients at the 1-year follow-up. The drug retention rate of tofacitinib did not differ between bDMARD-failure (155 per 2.4 years) and -naive patients (89 per 1.9 years) (log-rank test, p=0.202). In logistic regression, the positivity of RF and ACPA were associated with reduced drug retention (p=0.01 and 0.02, respectively). Totally 83 (27.7%) of patients had adverse, and 14 (4.7%) patients had herpes zoster infection. CONCLUSIONS: Nationwide real-world data showed that tofacitinib therapy is effective in patients with RA independent of previous use of a bDMARD. The drug retention of tofacitinib did not differ between bDMARD-failure and -naive patients, and RF or ACPA positivity may be associated with reduced discontinuation of tofacitinib.-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntirheumatic Agents-
dc.subject.MESHArthritis, Rheumatoid-
dc.subject.MESHBiological Products-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHJanus Kinase Inhibitors-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPyrroles-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHRheumatology-
dc.subject.MESHTreatment Outcome-
dc.titleEfficacy and drug retention of tofacitinib in rheumatoid arthritis: from the nationwide Korean College of Rheumatology Biologics registry-
dc.typeArticle-
dc.identifier.pmid36062753-
dc.contributor.affiliatedAuthorJung, JY-
dc.contributor.affiliatedAuthorKim, JW-
dc.contributor.affiliatedAuthorSuh, CH-
dc.contributor.affiliatedAuthorKim, HA-
dc.type.localJournal Papers-
dc.identifier.doi10.55563/clinexprheumatol/6fcyza-
dc.citation.titleClinical and experimental rheumatology-
dc.citation.volume41-
dc.citation.number5-
dc.citation.date2023-
dc.citation.startPage1034-
dc.citation.endPage1041-
dc.identifier.bibliographicCitationClinical and experimental rheumatology, 41(5). : 1034-1041, 2023-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1593-098X-
dc.relation.journalidJ00392856X-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Rheumatology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse